{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:24:57Z","timestamp":1793121897967,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40265-024-02129-x","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T02:54:50Z","timestamp":1735008890000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Arimoclomol: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020211","author":"C Tirelli","year":"2024","unstructured":"Tirelli C, Rondinone O, Italia M, et al. The genetic basis, lung involvement, and therapeutic options in Niemann-Pick disease: a comprehensive review. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14020211.","journal-title":"Biomolecules"},{"key":"2129_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073806","author":"IV Serv\u00edn Mu\u00f1oz","year":"2024","unstructured":"Serv\u00edn Mu\u00f1oz IV, Ortu\u00f1o-Sahag\u00fan D, Gri\u00f1\u00e1n-Ferr\u00e9 C, et al. Alterations in proteostasis mechanisms in Niemann-Pick Type C disease. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073806.","journal-title":"Int J Mol Sci"},{"key":"2129_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2023.101225","volume":"90","author":"FW Pfrieger","year":"2023","unstructured":"Pfrieger FW. The Niemann-Pick type diseases \u2013 a synopsis of inborn errors in sphingolipid and cholesterol metabolism. Prog Lipid Res. 2023;90:1\u201332.","journal-title":"Prog Lipid Res"},{"key":"2129_CR4","doi-asserted-by":"crossref","unstructured":"Petersen NHT, Klein P, Valacca C, et al. Arimoclomol increases the transcription of lysosomal genes, including NPC1 and NPC2, to facilitate lysosomal function [abstract no. 236 plus poster]. Mol Genet Metab. 2022;135(2):S96.","DOI":"10.1016\/j.ymgme.2021.11.251"},{"key":"2129_CR5","unstructured":"Zevra Therapeutics Inc. Arimoclomol: US prescribing information. 2024. https:\/\/zevra.com\/products\/#miplyffa. Accessed 23 Sep 2024."},{"key":"2129_CR6","unstructured":"Zevra Therapeutics Inc. Zevra Therapeutics\u2019 MIPLYFFA\u2122 (arimoclomol) receives U.S. FDA approval as treatment for Niemann-Pick disease Type C [media release]. 20 Sep 2024. https:\/\/investors.zevra.com."},{"key":"2129_CR7","unstructured":"Shammas H, Havns\u00f8e Torp Petersen N, Klein P, et al. Arimoclomol upregulates expression of genes belonging to the coordinated lysosomal expression and regulation (CLEAR) network [abstract no. 2013F plus poster]. In: American Society of Human Genetics Annual Meeting. 2024."},{"key":"2129_CR8","unstructured":"US Food & Drug Administration. FDA approves first treatment for Niemann-Pick disease, Type C [media release]. Sep 20 2024. https:\/\/www.fda.gov."},{"key":"2129_CR9","unstructured":"CytRx Corporation. CytRx Corporation relaunches as LadRx Corporation [media release]. 23 Sep 2022. http:\/\/www.ladrxcorp.com."},{"key":"2129_CR10","unstructured":"Corporation L. LadRx completes non-dilutive financing transaction for up to $11 million with XOMA corporation [media release]. 22 June 2023. https:\/\/www.ladrxcorp.com."},{"key":"2129_CR11","unstructured":"Xoma Corporation. XOMA acquires royalty and milestone economics to phase 3 first-in-class orphan disease asset for Niemann-Pick disease Type C (NPC) and phase 2 oncology asset [media release]. 22 June 2023. https:\/\/www.xoma.com."},{"key":"2129_CR12","unstructured":"KemPharm Inc. Correction: KemPharm announces corporate name change to Zevra Therapeutics [media release]. 22 Feb 2023. https:\/\/www.zevra.com."},{"key":"2129_CR13","unstructured":"KemPharm Inc. KemPharm announces strategic acquisition of arimoclomol from Orphazyme, expanding its rare CNS diseases pipeline [media release]. 15 May 2022. https:\/\/www.zevra.com."},{"key":"2129_CR14","unstructured":"Orphazyme A\/S. Orphazyme A\/S under in-court-restructuring to sell substantially all of its assets and business activities to KemPharm, Inc [media release]. 15 May 2022. https:\/\/www.orphazyme.com."},{"key":"2129_CR15","unstructured":"CytRx Corporation. CytRx completes sale of molecular chaperone assets to Orphazyme ApS in deal worth up to $120 million [media release]. 17 May 2011. http:\/\/www.ladrxcorp.com."},{"issue":"355","key":"2129_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9823","volume":"8","author":"T Kirkegaard","year":"2016","unstructured":"Kirkegaard T, Gray J, Priestman DA, et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci Transl Med. 2016;8(355): 355ra118.","journal-title":"Sci Transl Med."},{"key":"2129_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104374","volume":"86","author":"J Gray","year":"2022","unstructured":"Gray J, Fern\u00e1ndez-Su\u00e1rez ME, Falah M, et al. Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model. EBioMedicine. 2022;86: 104374.","journal-title":"EBioMedicine"},{"issue":"6","key":"2129_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/jimd.12428","volume":"44","author":"E Mengel","year":"2021","unstructured":"Mengel E, Patterson MC, Da Riol RM, et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2\/3 trial of a novel treatment. J Inherit Metab Dis. 2021;44(6):1463\u201380.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2129_CR19","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.ymgme.2021.11.026","volume":"135","author":"L Andersen","year":"2021","unstructured":"Andersen L, Petersen NH, Ingemann L, et al. Arimoclomol reduces levels of biomarkers of lipid burden in patients with Niemann-Pick disease type C [abstract no. 11]. Mol Genet Metab. 2021;135(2):S18.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2129_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-021-01719-2","volume":"16","author":"MC Patterson","year":"2021","unstructured":"Patterson MC, Lloyd-Price L, Guldberg C, et al. Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale. Orphanet J Rare Dis. 2021;16(1):79.","journal-title":"Orphanet J Rare Dis"},{"key":"2129_CR21","unstructured":"Patterson M, Guenther S, Dali C. Efficacy results from a 12-month double-blind randomised trial of arimoclomol for treatment of Niemann Pick disease Type C \u2013 presenting an improved 4-Domain NPC Clinical Severity Scale [abstract no. PO-210 plus poster 21260]. J Inherit Metab Dis. 2024;47(Suppl 1):189."},{"key":"2129_CR22","unstructured":"Patterson M, Mengel E, Guenther S, et al. Long-term efficacy and safety evaluation of arimoclomol treatment in patients with Niemann Pick Type C \u2013 data from 48 months open label trial [abstract no. PO-208 plus poster 21271]. J Inherit Metab Dis. 2024;47(Suppl 1):187\u20138."},{"key":"2129_CR23","unstructured":"Al-Hertani W, Berry-Kravis E, Wang R, et al. Arimoclomol for the treatment of NPC in a real-world setting: long-term outcomes from an expanded access program in the USA [abstract no. PO-212 plus poster]. J Inherit Metab Dis. 2024;47(Suppl 1):190."},{"key":"2129_CR24","unstructured":"Ficicioglu C, Berry-Kravis E, Al-Hertani W, et al. Arimoclomol safety profile in the treatment of NPC in a real-world setting: long-term data from an expanded access program in the USA [abstract no. PO-284 plus poster 20950]. J Inherit Metab Dis. 2024;47(Suppl 1):230\u20131."},{"key":"2129_CR25","unstructured":"Zevra Therapeutics Inc. Form 10-Q. 2024. https:\/\/investors.zevra.com\/. Accessed 10 Oct 2024."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02129-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02129-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02129-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:00:46Z","timestamp":1737079246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02129-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02129-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"19 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}